Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.
Among 470 patients with acquired immune deficiency syndrome and/or human immunodeficiency virus infection (HIV/AIDS) who underwent genotype resistance testing (GRT) after the failure of therapy, 17 (3.6%) harbored the Q151M mutation. The Q151M mutation was associated with younger age, lower CD4(+) lymphocyte count, higher HIV RNA level, and treatment with >2 pre-GRT regimens. By contrast, the Q151M mutation was inversely associated with lamivudine administration. A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients.
Zaccarelli
Mauro
M
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Rome, Italy. zaccarelli@inmi.it
Perno
Carlo Federico
CF
Forbici
Federica
F
Soldani
Fabio
F
Bonfigli
Sandro
S
Gori
Caterina
C
Trotta
Maria Paola
MP
Bellocchi
Maria Concetta
MC
Liuzzi
Giuseppina
G
D'Arrigo
Roberta
R
De Longis
Patrizio
P
Boumis
Evangelo
E
Bellagamba
Rita
R
Tozzi
Valerio
V
Narciso
Pasquale
P
Antinori
Andrea
A
D000328:Adult; D018432:Drug Resistance, Multiple / Q000235:genetics*; D005260:Female; D005973:Glutamine / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology; D008297:Male; D008715:Methionine / Q000235:genetics; D008826:Microbial Sensitivity Tests; D015999:Multivariate Analysis; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D012307:Risk Factors; D016879:Salvage Therapy
D018894:Reverse Transcriptase Inhibitors; D005973:Glutamine; D019259:Lamivudine; D008715:Methionine; D054303:HIV Reverse Transcriptase